Biotechnology: A sector built around practical scientific innovation

Genflow Biosciences Plc

Biotechnology uses living organisms, cells and biological processes to create products and solve practical problems. This is a sector where scientific progress can become commercial opportunity across healthcare, agriculture, industry and environmental applications.

At its simplest, biotechnology applies biology to product development. This can include using microorganisms to produce medicines, improving crops through genetic techniques, developing diagnostic tools, or creating cleaner industrial processes. The common thread is the use of biological systems to improve how products are made, how diseases are treated, or how resources are managed.

Healthcare is one of the most visible areas of biotechnology. Companies in this space may work on new medicines, vaccines, gene therapies or diagnostic tests. These products can address clear market needs, particularly where existing treatments are limited.

Biotechnology also has relevance beyond medicine. In agriculture, it can help improve crop performance, increase resistance to pests and support more efficient food production. In industrial settings, biological processes can be used to make chemicals, materials and fuels in ways that may reduce waste or environmental impact.

Genflow Biosciences plc (LON:GENF, OTCQB:GENFF, FRA:WQ5) is a UK-based biotech firm with R&D facilities in Belgium focused on developing novel therapeutic approaches that potentially halt or slow the aging process in humans and dogs supporting longer, healthier lives

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Healthspan becomes a clearer investment theme in preventive wellness

Healthspan is becoming a stronger investment theme as consumers focus on daily habits that support healthier ageing.

Genflow Biosciences to Attend BIO San Diego as Chairman Gad Berdugo Joins mRNA Panel

Genflow Biosciences will attend BIO San Diego, with chairman Gad Berdugo joining an mRNA panel.

Genflow Biosciences to present SLAB study data at Animal Longevity Summit 2026

Genflow Biosciences has been invited to present data from its SLAB study at the Animal Longevity Summit in Toronto in October 2026.

Genflow Biosciences targets longevity market with gene therapy approach

Genflow Biosciences is positioning its SIRT6 gene therapy platform within the growing longevity biotech sector, where investors are increasingly focused on clinical evidence and clear development pathways.

Genflow Biosciences to hold AGM on 29 June 2026

Genflow Biosciences Plc will hold its Annual General Meeting at 11am on Monday 29 June 2026 at One Heddon Street, London. The Notice of AGM, Form of Proxy, and 2025 Annual Report are available on the company’s website.

Healthspan takes centre stage in the longevity market

Longevity is moving beyond promises of longer life as consumers focus on healthspan, prevention and practical ways to age better.

Search